Hyundai ADM Bio Voluntarily Withdraws IND for Clinical Study of Docetaxel Combination Cancer Therapy to Focus on Immunotherapy Strategy
Declares a strategic pivot to lead the post-patent immunotherapy combination era SEOUL, South Korea, May 13, 2025 /PRNewswire/ -- Hyundai ADM Bio (KOSDAQ symbol 187660) today announced the voluntary withdrawal of its Investigational New Drug (IND) application for Phase 1 clinical trial evaluating...
Hyundai ADM Demonstrates Anti-Metastatic Effect of 'PenetriumTM' in TNBC Preclinical Study
– Simultaneous treatment of primary and metastatic tumors by eliminating pseudo-resistance SEOUL, South Korea, March 27, 2025 /PRNewswire/ -- Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, PenetriumTM, showed significant a...
Hyundai ADM Unveils a "New Paradigm in Cancer Treatment" - Preclinical Study Shows Promise for Continuous Oral Chemotherapy with Lowered Side Effects Risks
SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- Hyundai ADM Bio (Co-CEOs Taek-Sung Kim and Kwang-Hee Kim) announced the results of its preclinical study on the oral anti-cancer drug OTX-M, developed from the well-known injectable chemotherapy drug docetaxel, at the "Biotech Showcase 2025" held ...
